Novo Nordisk's New Math: When Good News and Falling Shares Occupy the Same Chart
Published on 08/13/2026 at 12:52 | Redaktion boerse-global.de
There is a peculiar arithmetic at work in Copenhagen these days. Novo Nordisk raises its full-year guidance, and the stock drops. It secures a legal victory against a copycat product, and investors shrug. It buys back its own shares at a pace that suggests management sees value, and the market keeps marking the price lower. The Danish pharmaceutical giant is no longer being judged on whether it delivers — it is being judged on whether its era of dominance can survive contact with reality.
That reality has a number attached to it: 675 dollars. Starting in January 2027, Novo Nordisk will cut the list prices of Ozempic and Wegovy to that monthly figure. The decision, announced this week, is a direct response to political pressure from Washington and the intensifying challenge from Eli Lilly, which analysts expect to capture a disproportionate share of the US Medicare market. A company that once set prices with impunity is now negotiating with the market it created.
A Quarter That Should Have Been Better
The second-quarter numbers, reported on August 4, told a story of operational resilience wrapped in investor disappointment. Revenue reached 78.49 billion Danish kroner, up 3 percent on a comparable basis, with adjusted sales climbing 7 percent. Management responded by lifting its annual outlook, now projecting adjusted revenue growth of between 0 and minus 6 percent on a comparable basis, alongside a matching range for adjusted operating profit — an improvement over the May guidance.
None of it was enough. US-listed shares fell around 6 percent as the market digested the news. The culprit was partly the oral Wegovy pill, which generated 3.22 billion kroner in the quarter — just shy of the 3.27 billion analysts had penciled in. More than five million prescriptions since the January launch is objectively a strong debut, but Novo Nordisk is no longer measured against objective standards. It is measured against the expectations its own success created.
The company itself points to softening US sales ahead, citing prescription trends for GLP-1 injections, intensifying competition, and reduced Medicaid coverage for obesity medications. A market once viewed as nearly limitless is showing friction.
The Pipeline's Uncomfortable Message
The mood darkened further in late July when Ziltivekimab missed its primary endpoint in the Phase 3 ZEUS trial, failing to reduce cardiovascular events with a hazard ratio of 0.99. Shares in Copenhagen fell 7.42 percent in a single session. Management insists the setback does not affect the 2026 profit forecast, though a non-cash impairment will hit the third quarter.
That charge follows a 6.3 billion kroner writedown on pipeline assets already booked in the second quarter, including 4.0 billion kroner tied to Monlunabant alone. Add CagriSema to the ledger: weight loss of 23 percent in trials, versus market expectations of roughly 25 percent. The pattern is unmistakable. A company carried for years by a single class of drugs is discovering that not every bet pays off.
Just as Novo Nordisk is learning that relying on a single product line carries risk, many employers discover too late that missing safety documentation can be just as costly. A free toolkit with 41 ready-to-use templates and checklists helps you document workplace risks properly — from fire safety to manual handling — so you can protect your team and your business. Download the free Risk Assessment Toolkit
Fighting on Multiple Fronts
Novo Nordisk is responding with a three-pronged strategy that spans the courtroom, the cloud, and the capital markets. In early August, a court in The Hague issued a preliminary injunction against Dutch pharmacy Ceban Ziekenhuisfarmacie, which had been selling an imitation semaglutide nasal spray despite no such formulation being approved anywhere in the world. The company's supplementary protection certificate extends semaglutide patent protection until March 19, 2031 — a reminder that Novo Nordisk intends to defend its intellectual property aggressively even as approved competitors multiply.
On August 10, the company announced a strategic partnership with Amazon Web Services to accelerate drug discovery and operations through agent-based AI and cloud technologies, with a joint innovation hub planned for London. AWS becomes Novo Nordisk's preferred cloud and AI partner. Whether such investments move the share price in the near term is doubtful, but they signal that the race for the next generation of treatments will not be left to chance.
Meanwhile, the buyback program continues quietly. Since February, Novo Nordisk has repurchased nearly 27.9 million B-shares at an average price of 279.01 kroner, part of a 15 billion kroner, twelve-month program. As of August 7, the company was still buying. Management's conviction that the stock is cheap is not shared by the market — but it is being expressed in action rather than words.
A Stock Between Support and Skepticism
The share closed Wednesday at 40.14 euros, down 2.1 percent on the day and roughly 27 percent below its 52-week high of 54.86 euros from January. The stock trades 3.7 percent below its 50-day average and 1.4 percent below its 200-day average, with an RSI of 41.6 — technically in no man's land, neither oversold nor euphoric. Year to date, the loss stands at 9.7 percent.
Berenberg this week downgraded the shares to "Hold," arguing that the excitement around oral Wegovy — once the central growth narrative — is already reflected in the price. The market capitalization of 181 billion euros keeps Novo Nordisk among Europe's largest pharmaceutical companies, and some analysts consider the valuation attractive, with a price-to-earnings ratio well below the sector average.
The company has not been idle on the commercial front either. Awiqli, the first once-weekly basal insulin, has launched in the US, and production capacity expansion continues aggressively. In the first half of 2026, Novo Nordisk distributed 41.2 billion Danish kroner to shareholders.
Managing risk isn't just about financial exposure — workplace safety carries its own legal obligations. Over 37,000 UK businesses already use a free Health & Safety toolkit with risk assessments, checklists, and toolbox talks covering key regulations like COSHH and PUWER. Get the free Health & Safety Toolkit
The next quarterly results arrive on November 4, covering the first three quarters of 2026. Two cardiovascular studies, HERMES and ARTEMIS, will not report until the first half of 2027. Between now and then, the market will be watching one thing above all: whether a company that once defined a category can convince investors that its future is not merely a defense of the past. The January 2027 price cut will be the first real test of whether Novo Nordisk can compete in the market it built — or whether it has already surrendered the pricing power that made it exceptional.
